Crinetics Pharmaceuticals
CRNX
227 hedge funds and large institutions have $3.42B invested in Crinetics Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 90 increasing their positions, 73 reducing their positions, and 55 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 73
2.02% more ownership
Funds ownership: 107.49% → 109.51% (+2%)
8% less funds holding
Funds holding: 247 → 227 (-20)
33% less capital invested
Capital invested by funds: $5.1B → $3.42B (-$1.68B)
35% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 55
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
74% less call options, than puts
Call options by funds: $1.4M | Put options by funds: $5.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$191M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$56M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$23.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$19.8M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$75.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$31.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$23.5M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
-$23.2M |
CRNX Hedge Fund Activity: Q1 2025 in Review
227 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2025, worth a combined $3.42B — down 33% from $5.1B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of CRNX and 36 opened new positions — a net loss of 19 holders — while 73 trimmed existing stakes and 90 added.
The largest buyer was Fidelity Investments, adding an estimated $191M. The largest seller was Point72 Asset Management, cutting an estimated $75.1M.
- 227 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2025, down from 247 in Q4 2024.
- Funds reported $3.42B of Crinetics Pharmaceuticals stock for Q1 2025, down 33% quarter-over-quarter.
- 36 funds opened new Crinetics Pharmaceuticals positions in Q1 2025 and 55 closed out, a net change of -19 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2025 was Fidelity Investments, an estimated $191M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2025 was Point72 Asset Management, an estimated $75.1M sold.
Based on aggregated 13F filings for Q1 2025.